- Home
- LX vs MRVI Comparison
LX vs MRVI Comparison
Compare LX & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | MRVI |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.1M | 538.0M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LX | MRVI |
|---|---|---|
| Price | $2.71 | $3.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.50 | ★ $4.57 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 03-17-2026 | 02-24-2026 |
| Dividend Yield | ★ 14.37% | N/A |
| EPS Growth | ★ 125.70 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $1,933,903,250.00 | $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | $1.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $1.67 |
| 52 Week High | $11.64 | $5.10 |
Technical Indicators
Market Signals| Indicator | LX | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 25.46 | 38.09 |
| Support Level | $2.98 | $3.30 |
| Resistance Level | $2.90 | $3.51 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 8.77 | 12.87 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.